FibroBiologics has initiated a clinical trial for CYWC628, a fibroblast-based therapy aimed at treating diabetic foot ulcers (DFUs), a condition affecting over 33 million people globally with limited effective treatments. This milestone marks a shift from development to clinical execution, with patient enrollment starting in Q2 2026 and topline data expected by the end of 2026. The company also continues advancing other programs in multiple sclerosis, psoriasis, and immune function restoration, backed by a strong patent portfolio and sufficient capital to support ongoing trials. This progress reflects FibroBiologics' strategy to address chronic diseases through innovative cell therapies.
Barclays increased its price target for Carvana to $94 and maintained an "Overweight" rating, reflecting confidence in the company's strong operational growth, including a 40% rise in retail unit sales and a record Adjusted EBITDA of $672 million. Ho...
An Exxon Mobil executive sold shares valued between $15,000 and $50,000 after the company's stock surged over 150% in five years, trading near its 52-week high. The strong performance is driven by favorable market conditions, including geopolitical t...
East West Bancorp is set to report strong Q2 2026 earnings with an expected EPS of $2.61 and revenue of $785.94 million, reflecting an 11.8% revenue increase and 14.5% EPS growth year-over-year. The bank shows robust financial health with expanding d...
AerCap has selected GE Aerospace's GEnx-1B engines to power 15 additional Boeing 787 Dreamliners, reinforcing its position as the largest owner of these aircraft. The GEnx engine is known for its high reliability and long service life, with a 99.98% ...
Crédit Agricole Brie Picardie conducted share buybacks totaling 13,057 shares from July 13 to July 17, 2026, with daily volumes ranging from 1,605 to 5,095 shares. These transactions were carried out under Article 5 of the Market Abuse Regulation (MA...
